🚨 The FDA has issued an early alert for Boston Scientific's ENROUTE Transcarotid Neuroprotection System due to potential arterial sheath tip se… #BostonScientific #Catheter #FDAalert #Medicaldevicesafety #Strokeprevention

The FDA has approved asundexian, the first factor XIa inhibitor indicated to reduce recurrent stroke after a noncardioembolic ischemic stroke or high-risk TIA, based on phase 3 OCEANIC-STROKE data.

Mukul Sharma, MD, discusses results of the OCEANIC-STROKE trial evaluating the role of XIa inhibitor asundexian for secondary stroke prevention.

The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.”

The Spanish Society of Neurology warns that stroke remains a leading global killer, with 90,000 new cases reported in Spain every year.

A stroke can strike without warning, leaving little time to react. Knowing the symptoms and seeking immediate medical care can significantly improve a person’s chances of survival and long-term recovery.

Missing blood pressure medication could mean losing much of its protection against heart attacks and strokes, according to an analysis of more than 91,000 people. Patients who consistently took their...